AAA is a radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicines. The Offer and withdrawal rights expired as scheduled at 12:00 midnight, New York City Time, on January 19, 2018. ( AAAP) ("AAA"), for a price of USD 41.00 per Ordinary Share and USD 82.00 per ADS, in each case payable net to the seller in cash, without interest (the "Offer"). Radioligand therapy (RLT) pipeline includes 177Lu-PSMA-R2 entering Phase 1/2 study for prostate cancerīasel, JanuNovartis AG ( NVS) today announced the successful completion of the tender offer by its subsidiary, Novartis Groupe France S.A., to purchase all of the outstanding ordinary shares ("Ordinary Shares"), including Ordinary Shares represented by American Depositary Shares ("ADSs"), of Advanced Accelerator Applications S.A. Lutathera® (lutetium Lu 177 dotatate), with a US PDUFA date of January 26, creates anticipation for NET portfolio expansion Other liabilities (incl.Transaction expands Novartis Oncology neuroendocrine tumor (NET) treatment portfolio and adds radiopharmaceutical technology platform Provisions for pensions and similar obligations Result from discontinued operations (net of tax) Recurring pretax income from continuing operations Source: Company data, Hauck & Aufhäuser Close price as of: BUY with an unchanged PT of € 172 based on SOTP. Ga-68,Y-90,Lu-177, etc.) and auxiliary products and services continues to benefit from a wider adoption of the radioligand therapies, it also holds a significant value optionality via its 83% stake in Pentixapharm. Novartis, Bayer), which should catalyze significant value.Īll in all, while EUZ's core business with radioisotopes (e.g. In our view, the most likely exist strategy for EUZ should be a complete sale or a licensing agreement with a big pharmaceutical company (e.g. This seems reasonable considering multi- billion price tags Novartis paid for radioligand assets (AAA: NETSPOT/Lutathera, Endocyte: PSMA-617) and the fact that this space remains en vogue.
![netspot novartis netspot novartis](https://s3.amazonaws.com/tracxnassets/cdn/screenshots/domain-profile/httpswwwadacapcom_23Jc6bnqyD_ZuaDI7xFky.jpeg)
In fact, based on the initial indications (multiple myeloma, non-hodgkin lymphoma and acute myeloid leukemia) with a combined global annual incidence rate of more than 290,000, Pentixafor could be worth $ 1bn. The IIS once again underscores the high interest and the potential of this compound in staging and potentially treatment of a range of cancers. This enables to generate additional clinical data beyond the scope of regular clinical trials. NB: IIS are clinical investigations that are started by physicians, as opposed to pharmaceutical companies. Yesterday, EUZ announced that a renowned university hospital in France has launched an investigator-initiated study (IIS) to evaluate the potential of the Ga-68-based diagnostic (Pentixafor) in patients with symptomatic multiple myelomas.
Netspot novartis trial#
Crucially, the trial results can be recognised in the US via the mutual recognition agreements (MRA) framework. An approval could be possible in Q1 2024. The trial is scheduled to start in mid-2022 involving more than 500 patients at 20+ treatment sites in Europe, the US and Australia. The totality of earlier clinical evidence of the Ga-68 based diagnostic agents (Pentixafor) documented in 14 preclinical and 54 clinical publications covering almost 900 patients allowed EUZ to directly proceed into Phase 3 trial in Europe, saving significant time. Overtime it has helped with financing and obtained an 83% stake in Pentixapharm at total costs of approximately € 30m. In 2020, EUZ identified a well-researched, yet commercially overlooked radioligand asset directed at CXCR4 receptor, which is implicated in the development and metastasis of a number of tumors.